📊 ELVN Key Takeaways
Is Enliven Therapeutics, Inc. (ELVN) a Good Investment?
Enliven Therapeutics is a pre-revenue biopharmaceutical company burning significant cash with negative operating margins of -119.7M and declining net losses, indicating the company is in early development stages without commercial product generation. While the balance sheet shows strong liquidity (28.66x current ratio) and minimal debt, the company is consuming approximately $70M in operating cash annually with only $98.9M in cash reserves, providing limited runway without achieving revenue milestones or securing additional financing.
Enliven Therapeutics has the balance sheet profile of a well-capitalized clinical-stage biotech, with very high liquidity, minimal liabilities, and no meaningful debt. However, the business remains pre-revenue and deeply unprofitable, with sizable operating and free cash flow burn that makes future value creation highly dependent on successful clinical execution rather than current operating fundamentals. The modest improvement in EPS is encouraging, but core profitability and self-funding capacity remain absent.
Why Buy Enliven Therapeutics, Inc. Stock? ELVN Key Strengths
- Strong balance sheet with $459.6M stockholders equity and minimal debt (0.00x debt-to-equity)
- Excellent liquidity position with $98.9M cash and 28.66x current ratio providing financial flexibility
- Net losses improving year-over-year (declining 16.5% from prior period) suggesting operational progress toward development goals
- Exceptional liquidity with current and quick ratios of 28.66x
- Strong balance sheet with $459.60M of equity and essentially no leverage
- Net loss and diluted EPS showed year-over-year improvement despite continued R&D investment
ELVN Stock Risks: Enliven Therapeutics, Inc. Investment Risks
- Zero revenue generation indicating no commercial products on market and high execution risk for clinical programs
- Negative operating cash flow of -$70.3M annually with limited cash runway of approximately 1.4 years at current burn rate without revenue
- Negative ROE (-22.6%) and ROA (-21.8%) reflecting value destruction with no clear path to profitability; typical pre-revenue biotech development risk
- 23 Form 4 insider filings in 90 days suggesting potential insider selling or equity compensation dilution
- No revenue base, making the company fully dependent on pipeline progress and external financing over time
- Large operating loss of $119.66M and negative free cash flow of $70.46M indicate sustained cash burn
- Profitability metrics remain weak, with negative ROE and ROA showing capital is not yet generating returns
Key Metrics to Watch
- Cash burn rate and time to cash depletion; need for future financing rounds
- Clinical trial progress and regulatory milestones for lead programs
- Changes in cash position and additional capital raises that extend runway
- Quarterly operating cash burn relative to cash and equivalents
- Any transition from pre-revenue status toward collaboration revenue, milestone revenue, or eventual product sales
Enliven Therapeutics, Inc. (ELVN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 28.66x current ratio provides a solid financial cushion.
ELVN Profit Margin, ROE & Profitability Analysis
ELVN vs Healthcare Sector: How Enliven Therapeutics, Inc. Compares
How Enliven Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Enliven Therapeutics, Inc. Stock Overvalued? ELVN Valuation Analysis 2026
Based on fundamental analysis, Enliven Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Enliven Therapeutics, Inc. Balance Sheet: ELVN Debt, Cash & Liquidity
ELVN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Enliven Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.89 indicates the company is currently unprofitable.
ELVN Revenue Growth, EPS Growth & YoY Performance
Enliven Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ELVN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Enliven Therapeutics, Inc. (CIK: 0001672619)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 27, 2026 | 4 | xslF345X06/form4-03272026_080317.xml | View → |
| Mar 19, 2026 | 4 | xslF345X06/form4-03192026_090347.xml | View → |
| Mar 11, 2026 | 4 | xslF345X05/form4-03112026_090319.xml | View → |
| Mar 10, 2026 | 4 | xslF345X05/form4-03102026_100318.xml | View → |
| Mar 3, 2026 | 10-K | elvn-20251231.htm | View → |
❓ Frequently Asked Questions about ELVN
What is the AI rating for ELVN?
Enliven Therapeutics, Inc. (ELVN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELVN's key strengths?
Claude: Strong balance sheet with $459.6M stockholders equity and minimal debt (0.00x debt-to-equity). Excellent liquidity position with $98.9M cash and 28.66x current ratio providing financial flexibility. ChatGPT: Exceptional liquidity with current and quick ratios of 28.66x. Strong balance sheet with $459.60M of equity and essentially no leverage.
What are the risks of investing in ELVN?
Claude: Zero revenue generation indicating no commercial products on market and high execution risk for clinical programs. Negative operating cash flow of -$70.3M annually with limited cash runway of approximately 1.4 years at current burn rate without revenue. ChatGPT: No revenue base, making the company fully dependent on pipeline progress and external financing over time. Large operating loss of $119.66M and negative free cash flow of $70.46M indicate sustained cash burn.
What is ELVN's revenue and growth?
Enliven Therapeutics, Inc. reported revenue of N/A.
Does ELVN pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
Where can I find ELVN SEC filings?
Official SEC filings for Enliven Therapeutics, Inc. (CIK: 0001672619) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELVN's EPS?
Enliven Therapeutics, Inc. has a diluted EPS of $-1.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELVN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Enliven Therapeutics, Inc. has a SELL rating with 82% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELVN stock overvalued or undervalued?
Valuation metrics for ELVN: ROE of -22.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELVN stock in 2026?
Our dual AI analysis gives Enliven Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELVN's free cash flow?
Enliven Therapeutics, Inc.'s operating cash flow is $-70.3M, with capital expenditures of $158.0K.
How does ELVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -22.6% (avg: 15%), current ratio 28.66 (avg: 2).